TY - JOUR
T1 - Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome
AU - Rechtman, Ehud
AU - Allen, Valerie D.
AU - Danis, Ronald P.
AU - Pratt, Linda M.
AU - Harris, Alon
AU - Speicher, Matthew A.
PY - 2003/10/1
Y1 - 2003/10/1
N2 - PURPOSE: To report the effects of intravitreal triamcinolone acetonide injections for subfoveal and juxtafoveal choroidal neovascularization (CNV) in ocular histoplasmosis syndrome. METHODS: In a retrospective analysis, the proportion of eyes that gained ≥5 or lost ≥5 and ≥15 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters, best-corrected visual acuity using ETDRS letter score (VA), greatest linear dimension (GLD), and treatment side effects were assessed. RESULTS: Ten patients (five subfoveal, five juxtafoveal CNV; median follow-up: 17 months; range, 6-41 months) were evaluated. Thirty percent gained ≥5 letters, 20% lost 5 to 14 letters, and 50% maintained stable VA. Overall, mean VA and GLD remained stable. Side effects were transient intraocular pressure elevation and mild cataract development. CONCLUSIONS: Intravitreal triamcinolone acetonide for CNV resulting from OHS was found to be relatively safe and showed good visual outcome for both subfoveal and juxtafoveal CNV. Further studies are warranted to evaluate this treatment.
AB - PURPOSE: To report the effects of intravitreal triamcinolone acetonide injections for subfoveal and juxtafoveal choroidal neovascularization (CNV) in ocular histoplasmosis syndrome. METHODS: In a retrospective analysis, the proportion of eyes that gained ≥5 or lost ≥5 and ≥15 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters, best-corrected visual acuity using ETDRS letter score (VA), greatest linear dimension (GLD), and treatment side effects were assessed. RESULTS: Ten patients (five subfoveal, five juxtafoveal CNV; median follow-up: 17 months; range, 6-41 months) were evaluated. Thirty percent gained ≥5 letters, 20% lost 5 to 14 letters, and 50% maintained stable VA. Overall, mean VA and GLD remained stable. Side effects were transient intraocular pressure elevation and mild cataract development. CONCLUSIONS: Intravitreal triamcinolone acetonide for CNV resulting from OHS was found to be relatively safe and showed good visual outcome for both subfoveal and juxtafoveal CNV. Further studies are warranted to evaluate this treatment.
UR - http://www.scopus.com/inward/record.url?scp=0141793688&partnerID=8YFLogxK
U2 - 10.1016/S0002-9394(03)00389-1
DO - 10.1016/S0002-9394(03)00389-1
M3 - Article
C2 - 14516819
AN - SCOPUS:0141793688
SN - 0002-9394
VL - 136
SP - 739
EP - 741
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
IS - 4
ER -